Skip to main content

Table 1 Clinical Characteristics of 147 Hospitalized Patients

From: Comparison of the duration of viral RNA shedding and anti-SARS-CoV-2 spike IgG and IgM antibody titers in COVID-19 patients who were vaccinated with inactivated vaccines or not: a retrospective study

 

Total (n = 147)

UV (n = 46)

PV (n = 28)

FV (n = 73)

P

Gender

    

0.524

 Male, No. (%)

65 (44.2)

20 (43.5)

15 (53.6)

30 (41.1)

 

 Female, No. (%)

82 (55.8)

26 (56.5)

13 (46.4)

43 (58.9)

 

Age, years

53 (35–61)

55.5 (32.5–69.25)

57 (38.5–65)

47 (35.5–58)

0.069

BMI, kg/m2

22.2 (20.83–24.74)

21.88 (20.74–24.77)

22.69 (20.61–24.72)

22.2 (20.9–24.56)

0.885

Current Smoking, No. (%)

61 (41.5)

18 (39.1)

14 (50)

29 (39.7)

0.596

Symptoms

     

 Fever, No. (%)

45 (30.6)

12 (26.1)

9 (32.1)

24 (32.9)

0.722

 Cough, No. (%)

63 (42.9)

19 (41.3)

11 (39.3)

33 (45.2)

0.837

 Diarrhea, No. (%)

6 (4.1)

2 (4.3)

1 (3.6)

3 (4.1)

 

 Sore throat, No. (%)

23 (15.6)

5 (10.9)

5 (17.9)

13 (17.8)

0.561

 Chills, No. (%)

1 (0.7)

0

1 (3.6)

0

 

 Abdominal pain, No. (%)

1 (0.7)

1 (2.2)

0

0

 

 Loss of smell, No. (%)

3 (2)

0

1 (3.6)

2 (2.7)

 

 Loss of taste, No. (%)

2 (1.4)

0

0

2 (2.7)

 

 Muscle pains, No. (%)

4 (2.7)

3 (6.5)

1 (3.6)

0

 

 Loss of appetite, No. (%)

2 (1.4)

1 (2.2)

0

1 (1.4)

 

 Dizziness, No. (%)

1 (0.7)

1 (2.2)

0

0

 

 Fatigue, No. (%)

13 (8.8)

4 (8.7)

6 (21.4)

3 (4.1)

0.023

 Stuffy nose, No. (%)

12 (8.2)

4 (8.7)

1 (3.6)

7 (9.6)

0.606

 Runny nose, No. (%)

11 (7.5)

3 (6.5)

2 (7.1)

6 (8.2)

0.940

 Chest tightness, No. (%)

1 (0.7)

1 (2.2)

0

0

 

 Headache, No. (%)

3 (2)

2 (4.3)

1 (3.6)

0

 

Asymptomatic, No. (%)

26 (17.7)

10 (21.7)

5 (17.9)

11 (15.1)

0.649

Comorbidities, No. (%)

54 (36.7)

22 (47.8)

13 (46.4)

19 (26)

0.028

 Hypertension, No. (%)

40 (27.2)

16 (34.8)

10 (35.7)

14 (19.2)

0.094

 Diabetes, No. (%)

10 (6.8)

4 (8.7)

1 (3.6)

5 (6.9)

 

 Coronary heart disease, No. ()

9 (6.1)

4 (8.7)

1 (3.6)

4 (5.5)

 

 Chronic pulmonary disease,

No. (%)

3 (2)

1 (2.2)

1 (3.6)

1 (1.4)

 

 Chronic liver disease, No. (%)

1 (0.7)

0

0

1 (1.4)

 

 Cancer, No. (%)

2 (1.4)

1 (2.2)

1 (3.6)

0

 

 Chronic kidney disease,

No. (%)

2 (1.4)

1 (2.2)

1 (3.6)

0

 

 Hypothyroidism, No. (%)

1 (0.7)

1 (2.2)

0

0

 

 Rheumatoid Arthritis, No. (%)

1 (0.7)

1 (2.2)

0

0

 

 History of cerebral hemorrhage, No. (%)

2 (1.4)

1 (2.2)

0

1 (1.4)

 

 Arrhythmia, No. (%)

2 (1.4)

1 (2.2)

1 (3.6)

0

 

Complications

32 (21.8)

15 (32.6)

5 (17.9)

12 (16.4)

0.098

 Liver dysfunction, No. (%)

49 (33.3)

19 (41.3)

6 (21.4)

24 (32.9)

0.211

 Renal dysfunction, No. (%)

55 (37.4)

21 (45.7)

11 (39.3)

23 (31.5)

0.292

Treatment

     

Thymosin α1, No. (%)

32 (21.8)

7 (15.2)

5 (17.9)

20 (27.4)

0.250

Days from illness onset to hospital admission

2 (1–3)

2 (1–3)

2.5 (1–4)

2 (1–3)

0.336

Ct value

29.48 ± 5.99

27.84 ± 5.44

29.48 ± 6.55

30.52 ± 5.94

0.057

  1. Data are presented as median (interquartile range) or mean ± standard deviation or the number (percentage). Continuous variables were analyzed by variance analysis or Kruskal‒Wallis test. Categorical variables were compared using the chi-square (χ2) test or Fisher’s exact test. A P value of less than 0.05 (two-tailed) was considered statistically significant
  2. FV fully vaccinated, PV partially vaccinated, UV unvaccinated, ct SARS-CoV-2 nucleocapsid gene cycle threshold (ct) value